Types Two types of insulin pens are available on the market: 1. Insulin ready-to-use pens (disposable pens, flexpens): with the insulin ampoules already inserted, they are ready for immediate use. When the ampoule is empty, the entire pen is disposed of. 2. Reusable insulin pens: the empty insulin ampoule is replaced with a new, filled … Insulin Pens
Products Insulin aspart is marketed as an injectable (NovoRapid, USA: NovoLog). It has been approved in many countries since 1999. The fixed combination IDegAsp (insulin aspart + insulin degludec, Ryzodeg) was registered in many countries and in the EU in 2013. In 2017, Fiasp ultra-fast-acting, a very fast-acting insulin aspart, was also approved. With the … Insulin Aspart
Products Dulaglutide was approved as a solution for injection in many countries in 2015 (Trulicity). Structure and properties Dulaglutide (ATC A10BJ05) is a fusion protein consisting of two identical chains linked by disulfide bridges. The chains contain: The GLP-1 analog (sequence segment 7-37), which is 90% the same as the natural GLP-1 segment. It has … Dulaglutide
Active ingredients Metformin (Glucophage, generics, combination products) Detailed information. Buformin (off label) Phenformin (out of trade)
Products Canagliflozin is commercially available in the form of film-coated tablets (Invokana). It was approved in the United States and EU in 2013 and in many countries in 2014. Vokanamet is a fixed combination of canagliflozin and metformin. It was also registered in many countries in 2014. Structure and properties Canagliflozin (C24H25FO5S, Mr = 444.5 … Canagliflozin
Products Rosiglitazone was commercially available in tablet form (Avandia). It had been approved since 1999 and was also commercially available in fixed combination with the biguanide metformin (Avandamet). The combination with the sulfonylurea glimepiride (Avaglim, EU, off-label) was not approved in many countries. A publication in on possible cardiovascular risks led to a controversy about … Rosiglitazone
Products Phenformin has been off the market in many countries since the late 1970s because of the potential adverse effects. Structure and properties Phenformin (C10H15N5, Mr = 205.3 g/mol) is a biguanide with a similar structure to metformin. Phenformin was the first agent in this group of drugs. Effects Phenformin (ATC A10BA01) has antidiabetic and … Phenformin
Products Vildagliptin is commercially available in tablet form as a monopreparation (Galvus) and in fixed combination with metformin (Galvumet). It has been approved in the EU since 2007 and in many countries since 2008. Generic versions were registered in 2020. Structure and properties Vildagliptin (C17H25N3O2, Mr = 303.40 g/mol) is a hydroxy-adamantane, a carbonitrile and … Vildagliptin
Products Chlorpropamide was commercially available in many countries in tablet form as a fixed combination with metformin (Diabiformin). The drug was approved in 1971 and is no longer available. Structure and properties Chlorpropamide (C10H13ClN2O3S, 276.74 g/mol) is a white crystalline powder that is practically insoluble in water. Effects Chlorpropamide (ATC A10BB02) has antidiabetic properties. Indications … Chlorpropamide
Products Pioglitazone is commercially available in tablet form (Actos, generics). It is also available as a fixed-dose combination with metformin (Competact). Pioglitazone has been approved in many countries since 2000. Structure and properties Pioglitazone (C19H20N2O3S, Mr = 356.4 g/mol) belongs to the thiazolidinediones. It is present in drugs as a racemate and as pioglitazone hydrochloride, … Pioglitazone
Products Semaglutide was approved in the US and EU in 2017 and in many countries in 2018 as a solution for injection (Ozempic). The agent is structurally and pharmacologically related to liraglutide (Victoza), which, unlike semaglutide, is injected once daily (both Novo Nordisk). In 2019, tablets containing semaglutide were approved for the first time in … Semaglutide
Products Troglitazone (Rezulin, tablets) is not commercially available in many countries. It was approved in 1997 and withdrawn from the market in 2000 because of its liver-toxic properties. Structure and properties Troglitazone (C24H27NO5S, Mr = 441.5 g/mol) belongs structurally to the thiazolidinediones. Effects Troglitazone (ATC A10BG01) is antidiabetic. Effects are due to agonism at the … Troglitazone
